PO-36 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial. Issue 200 (April 2021) - Marshall, A.; Young, A.M.; Levine, M.; Hill, C.; Hale, D.; Thirlwall, J.; Wilkie, V.; French, K.; Kakkar, A.K.; Lokare, A.; Maraveyas, A.; Chapman, O.; et al.